Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus CEFOXITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus CEFOXITIN.
CEFOTETAN vs CEFOXITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-1 and PBP-3, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis. This leads to cell lysis and death. It is resistant to beta-lactamases produced by many Gram-negative and Gram-positive bacteria.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
1-2 g IV every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefoxitin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefoxitin."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
3-4.5 hours (6-8 hours in renal impairment).
Terminal elimination half-life is approximately 0.7–1.1 hours (mean 0.8 h) in adults with normal renal function, extending to 5–10 hours in severe renal impairment (CrCl <10 mL/min).
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Renal excretion of unchanged drug accounts for approximately 85% of elimination; biliary excretion is minimal (<1%); fecal elimination is negligible.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."